- SEK2.01bn
- SEK1.43bn
Brief: Index Pharmaceuticals Updates Timeline Of Phase III Study CONCLUDE
Brief: Index Pharmaceuticals Holding Q3 Oper Loss Narrows To SEK 4.5 Mln
Brief: Jenny Sundqvist Appointed New CEO Of InDex Pharmaceuticals
Brief: Index Pharmaceuticals Q2 Operating Loss At SEK 21.7 Mln
Brief: Index Pharmaceuticals Gets New Patent For Cobitolimod Granted In Europe
Brief: InDex Pharmaceuticals Q1 Oper Loss Widens To SEK 18.9 Mln
Brief: Index Pharmaceuticals: CFO Johan Giléus Has Been Appointed Acting CEO
Brief: Index Pharmaceuticals Prepares For Commercialisation Of Cobitolimod
Brief: Index Pharmaceuticals Q4 Oper Loss Widens To SEK 22.7 Mln
Brief: Index Pharmaceuticals Says COO Pernilla Sandwall Has Decided To Leave Company To Become CEO Of WntResearch
Brief: Index Pharmaceuticals Enrols First Patient In Late-Stage Study Of Cobitolimod
Brief: Index Pharmaceuticals Holding Q3 Operating Loss Widens To SEK 28.2 Million
Brief: Index Pharmaceuticals Gets Patent For Cobitolimod In Canada
Brief: InDex Pharma Gets New Patent For Cobitolimod Granted In U.S.
Brief: Index Pharmaceuticals Gets Patent For Cobitolimod in US
Brief: InDex Pharmaceuticals Q2 Operating Loss Widens To SEK 42.6 Mln
Brief: Index Pharmaceuticals Receives FDA Clearance To Start The Phase III Study Conclude With Cobitolimod
Brief: Index Pharmaceuticals Receives First Regulatory Approval To Start The Phase III Study Conclude With cobitolimod
Brief: Index Pharmaceuticals Says Will Initiate Patient Recruitment For The Phase III Study CONCLUDE After The Summer